WCG IPO Presentation Deck

Our Investment Thesis - New Approaches to Addressing Clinical Trial Pain Points Dimensions of the Pain Point 1 # The Pain Point Lengthy IRB Review Slow Trial Startup Delayed Patient Enrollment Burdensome Administrative Processes Use of Disparate Technologies 12 (1) Reflects industry data. (2) WCG Performance. Up to 6 Months for IRB Reviews and A Different IRB for Every Site Little Improvement in the Past Few Years 85% of Trials Are Behind on Patient Enrollment Requires 6 Months to Negotiate Contracts and Budgets Between Biopharma & Sites On Average, 6 Different Technology Solutions Are Used In A Single Clinical Trial WCG Value DNL wcg 95% Improvement in IRB Review Time 50% Reduction to 6 Months 33% improvement 42% participant diversity in large biopharma COVID-19 trial 37% Improvement in Contracts & Budgets Negotiation Time Single Integrated Platform Supporting All Clinical Trial Stakeholders, Enabling Data-Driven Insights

View entire presentation